Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a ...

Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...

In a tough labor market where layoffs continue, some are considering—or even moving—from industry to academia, according to a ...

Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back ...